US 12,264,179 B2
Epstein-Barr Virus antigen constructs
Stefania Capone, Rome (IT); Antonella Folgori, Rome (IT); Armin Lahm, Rome (IT); and Benjamin Wizel, Rockville, MD (US)
Assigned to GlaxoSmithKline Biologicals SA, Rixensart (BE)
Filed by GLAXOSMITHKLINE BIOLOGICALS SA, Rixensart (BE)
Filed on Jul. 25, 2023, as Appl. No. 18/358,350.
Application 18/358,350 is a continuation of application No. 16/770,963, granted, now 11,773,139, previously published as PCT/IB2018/060101, filed on Dec. 14, 2018.
Claims priority of provisional application 62/608,038, filed on Dec. 20, 2017.
Prior Publication US 2024/0076318 A1, Mar. 7, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/005 (2006.01); A61K 39/00 (2006.01); A61K 39/245 (2006.01); C12N 7/00 (2006.01)
CPC C07K 14/005 (2013.01) [A61K 39/245 (2013.01); C12N 7/00 (2013.01); A61K 2039/70 (2013.01); C12N 2710/16222 (2013.01); C12N 2710/16234 (2013.01); C12N 2710/16271 (2013.01)] 44 Claims
 
1. A nucleic acid comprising:
(A) a polynucleotide encoding a polypeptide, the polypeptide comprising:
(a) an Epstein-Barr Virus (EBV) latent membrane protein 1 (LMP1) fragment, the EBV LMP1 fragment comprising one or more of SEQ ID NOs: 2-5;
(b) an EBV latent membrane protein 2 (LMP2) fragment, the EBV LMP2 fragment comprising one or more of SEQ ID NOs: 7-10;
(c) an EBV nuclear antigen 1 (EBNA1) fragment, the EBNA1 fragment comprising at least 8 amino acids of SEQ ID NO: 11;
(d) an EBV nuclear antigen 3A (EBNA3A) fragment, the EBNA3A fragment comprising one or more of SEQ ID NOs: 14-20; or
(e) an EBV ZEBRA fragment, the EBV ZEBRA fragment comprising one or both of SEQ ID NO: 22 or SEQ ID NO: 23;
wherein the polypeptide is at least 80% identical to SEQ ID NO: 24 or SEQ ID NO: 26; and
(B) a sequence that is capable of directing expression of the polypeptide in a host cell;
wherein the polynucleotide is operatively linked to the sequence that is capable of directing expression of said polypeptide in the host cell.